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Abstract




Patients—Adolescent and young adult females with a new diagnosis of cancer requiring
chemotherapy.
Interventions—None.
Main Outcome Measures—Participants were followed to assess measures of OR (serum
follicle-stimulating hormone, luteinizing hormone, estradiol, inhibin B, anti-mullerian hormone
(AMH), and antral follicle counts and mean ovarian volume) at 3 month intervals. Changes in OR
were quantified for both the acute impact of treatment using linear regression and the longitudinal
recovery after therapy using mixed effects models adjusted for baseline OR, use of alkylating
agent, and hormone use.
Results—46 women with at least 1 pretreatment and 2 post-treatment study visits were included
(mean follow-up 12 months). All measures of OR demonstrated significant changes during
chemotherapy. Alkylating agent exposure and baseline OR were associated with the magnitude of
impairment acutely, and pretreatment AMH levels were associated with the rate of recovery of
AMH post-treatment. In adjusted models, participants with a pretreatment AMH level >2 ng/mL
recovered at a rate of 11.9% per month after chemotherapy, whereas participants with
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pretreatment AMH levels ≤2 ng/mL recovered at a rate of 2.6% per month after therapy
(p=0.003).
Conclusion—Baseline OR and alkylating agent exposure effect the magnitude of acute changes
in OR from chemotherapy. The rate of recovery of AMH is impacted by pretreatment levels. This
should be considered during pretreatment fertility preservation counseling.
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Introduction
Cancer therapies have an adverse impact on reproductive function, increasing the risk of
early menopause and infertility (1). One of the recognized challenges in studying the
reproductive risks of cancer therapy is that outcomes such as fertility are difficult to capture
and menstrual function is not a reliable predictor of fertility (2–4). Measures of ovarian
reserve, including ultrasound measures (antral follicle count (AFC) and mean ovarian
volume (MOV)), and serum measures (inhibin B (INH), anti-mullerian hormone (AMH),
estradiol (E2), lutenizing hormone (LH) and follicle-stimulating hormone (FSH)) are useful
surrogate markers for fertility potential (3, 5). AMH in particular has emerged as a valuable
marker of ovarian reserve in women as it remains relatively stable throughout the menstrual
cycle and may not be affected by hormone use (6, 7).
Limited data exist describing changes in measures of ovarian reserve during and shortly
after completion of cancer treatment. While studies of older pre-menopausal women with
breast cancer suggest that baseline AMH predicts resumption of menses after chemotherapy
(8–10), no prospective study has examined changes in comprehensive measures of ovarian
reserve in adolescent and young women undergoing chemotherapy and attempted to identify
factors associated with these changes.
The primary objective of this study was to evaluate the effect of chemotherapy on
longitudinal measures of ovarian reserve in post-pubescent adolescents and women ≤35
years with cancer. In addition, this study sought to identify factors associated with changes
in ovarian reserve. We hypothesized that reduced baseline ovarian reserve, exposure to
alkylating agents and pelvic radiotherapy would be associated with acute changes in
measures of ovarian reserve during cancer therapy, and with a slower rate of recovery after
cancer therapy.
Materials and Methods
This study is part of a collaboration between the University of Pennsylvania (Penn),
Children’s Hospital of Philadelphia (CHOP), Children’s Memorial Hospital in Chicago
(CMH) and the University of North Carolina-Chapel Hill (UNC). Institutional review board
approval was obtained at each site and informed consent was obtained from participants.
The study included a visit prior to initiation of cancer therapy and then visits every three
months from chemotherapy initiation. Study visits included a questionnaire, physical
examination, pelvic ultrasonography, and hormone analysis.
Subjects—Post-menarchal, pre-menopausal participants with a new cancer diagnosis were
enrolled from four sites (Penn, CHOP, CMH, and UNC). Participants were required to be
between 11–35 years of age, have a uterus and two ovaries and anticipate treatment with
chemotherapy (with or without radiation). Participants were excluded if they had been
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pregnant or lactating within three months or if they had received any chemotherapy or
radiation treatment prior to enrollment.
Questionnaires—A structured interview included detailed information on demographics,
medical history, menstrual characteristics, pregnancies, infertility history, contraception,
medications, and substance use. Use of exogenous hormones was recorded at each visit,
including hormonal contraceptives, tamoxifen, gonadotropin-releasing hormone (GnRH)
agonists, and hormone replacement therapy.
Physical Examination—Height and weight were measured for calculating body mass
index (BMI).
Pelvic Ultrasonography—MOV and AFC were determined by ultrasonography for
participants at 3 sites with ultrasound capability. Transvaginal ultrasonography was
preferred, though transabdominal ultrasound was performed in participants uncomfortable
with the transvaginal approach. MOV was calculated using the ellipse formula (A × B × C ×
0.52). AFC was determined as the number of follicles 2–10 mm in average diameter for
subjects undergoing transvaginal ultrasonography when both ovaries were visualized.
Hormone Analysis—Blood samples were obtained at each study visit for determining
levels of FSH, LH, E2, INH, and AMH. In regularly menstruating participants an attempt
was made to collect hormone measures during the early follicular phase of the menstrual
cycle (days 1–4), particularly for follow-up visits.
All hormone assays were measured at Penn’s Clinical Translational Research Center using
FSH and E2 Coat-A-Count kits (Diagnostic Products Corporation) and INH and AMH
ELISA kits (Diagnostic Systems). The FSH immunoradiometric assay’s range is 1.5–100
mIU/mL, with a sensitivity of 0.7 mIU/mL and inter- and intraassay coefficients of variation
(cov) <6% and 4%, respectively. The E2 RIA’s range is 20–3,600 pg/mL, with a sensitivity
of 7 pg/mL and inter- and intra-assay cov <8.1% and 7%, respectively. The INH’s ELISA’s
range is 10–531 pg/mL, with a sensitivity of 7 pg/mL and inter- and intra-assay cov <8%
and <6%, respectively. The AMH ELISA’s range is 0.050–10.0 ng/mL, with a sensitivity of
0.025 ng/mL and inter- and intra-assay cov <8% and 5%, respectively.
Menstrual Function—Subjects were given a menstrual diary and asked to provide dates
for their two most recent menstrual cycles during the interview at each study visit. Self-
reported cycle length at baseline was recorded for participants not taking exogenous
hormones. At the first post-treatment study visit, presence of menstrual function was defined
as having any menses since cancer therapy started. For subsequent visits the time period was
since the previous visit.
Cancer Therapy—Diagnosis and treatment exposure data were obtained by abstracting
medical records. Treatment was summarized for chemotherapeutic type, duration,
cumulative dose, radiation dose and location. Alkylating agent dose scores (AAD) were
determined by assigning a score ranging from 1 to 3 for each agent received and summing
scores over all agents (11).
Data Analysis—Analysis included participants who had at least two post-treatment study
visits. Baseline characteristics and log-transformed hormone levels and ultrasound data were
summarized over the course of cancer therapy and recovery. Separate models were
developed to focus on the acute impact of cancer treatment (acute phase) and ovarian
recovery (recovery phase). A priori power calculations determined that 72 participants were
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required to be able to detect a difference of 1/3 of the standard deviation in the within-
woman change of log-transformed AMH from baseline to post-treatment with a power of
80% and type I error of 0.05. This report represents a preliminary analysis of the data of this
ongoing cohort study.
Acute Phase
The acute change (difference) in ovarian reserve measures over treatment course was
summarized by subtracting baseline from the first post-treatment value. This metric was
chosen to describe cumulative changes during treatment since participants had varying
lengths of treatment. Percent change was computed as the ratio of geometric mean hormone
levels (unadjusted), or back-transformed from multivariable linear regression models of log-
transformed hormone values. Risk factors of interest included age, baseline measures of
ovarian reserve, duration of cancer therapy, alkylator exposure, pelvic/abdominal radiation
exposure, presence of menstrual cycles, and exogenous hormone use. Continuous variables
were analyzed dichotomously with median cut points, with the exception of BMI which was
assessed as a continuous measure and age which was categorized in 5 year intervals.
Recovery phase
To investigate changes in ovarian reserve after the completion of therapy, log-transformed
hormone levels and ultrasound data were modeled using general linear or random effects
regression models over post-treatment visits. These models describe within-person change
over time while also accounting for correlations within individuals in addition to averaging
data across women. Various model assumptions were examined and a simple model
assuming a common linear trend for recovery fit the data adequately. We assumed that risk
factors could influence the recovery of ovarian reserve in two distinct ways. First, risk
factors may influence the level of ovarian reserve at the start of the recovery period. In
addition, risk factors may affect the rate of recovery over time. Examination of this later
influence was performed using statistical tests of interaction between time and each risk
factor.
Study data were collected and managed using REDCap electronic data capture tools hosted
at the University of Pennsylvania. Statistical analysis was performed using STATA v12.0
(StataCorp, College Station, TX).
Results
Eighty-one women between the ages of 15 and 35 have been enrolled in this study. Forty-six
women had sufficient visits to be included in this report. Thirty eligible women were
recruited from Penn, 7 from CMH, 6 from CHOP, and 3 from UNC.
Baseline characteristics are presented in Table 1. Most participants were Caucasian,
unmarried, normal weight, nulligravid, and college graduates. Forty-one percent (19/46) of
participants were diagnosed with breast cancer and 37% with hematologic malignancies.
Chemotherapy regimens for breast cancer and lymphoma participants were heterogeneous.
Seventy-two percent of participants received an alkylating agent and the median alkylator
score for all participants was 1 (range 0–4). The median length of cancer therapy was 91
days (range 30–257 days). Twelve women underwent radiation: 9 chest, 2 pelvic, and 1
upper abdominal. One participant underwent ovarian transposition prior to pelvic
radiotherapy. Five women had ovarian biopsy and one had oophorectomy for tissue banking
for fertility preservation. One participant with leukemia was initially treated with
chemotherapy and then relapsed during the follow-up period. Data collected post-bone
marrow transplant was censored.
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The total number of study visits for each participant ranged from 3–7, with a median of 4
visits. The average length of follow-up was 12.4 months including 9.3 months (range 1–17.3
months) of follow-up after completion of cancer therapy. Forty-three percent (20/46) and
29% reported amenorrhea at their first and second post-therapy visits, respectively.
Observed changes in ovarian reserve over the study are summarized in Supplemental Figure
1, demonstrating that ovarian reserve became impaired acutely and then began to recover
post-treatment.
Acute phase
For each ovarian reserve measure, the median difference between the baseline and the first
post-treatment measure is summarized in Table 2, representing the raw change as a result of
cancer therapy. The mean number of months elapsed from the last day of chemotherapy to
the first post-treatment study visit was 2.4 (SD=2.3). All measures of ovarian reserve had
statistically significant changes from baseline to the first post-treatment visit in unadjusted
models (p<0.001). As a result of cancer therapy, FSH rose 321%, LH rose 183%, AMH fell
89%, E2 fell 56%, INH fell 55%, MOV fell 46% and AFC fell 75% (Table 2).
Models adjusting for alkylator use and baseline measures of ovarian reserve (and exogenous
hormone for FSH and E2) confirmed independent statistically significant changes for FSH,
LH, and AMH (Table 2). Age of participants, menstrual function for those not on hormones,
and use of abdominal/pelvic radiotherapy were not associated with acute changes (data not
shown). For FSH, length of treatment was shown to impact the magnitude of change during
the acute phase. Participants whose cancer therapy lasted ≥90 days had larger increases in
FSH (554%) than those with treatment regimens lasting < 90 days (96%) (p<0.001). There
was a trend towards length of therapy increasing the magnitude of change for the other
measures of ovarian reserve, but this reached statistical significance only for FSH.
Models were constructed to assess factors associated with the levels of ovarian reserve at the
end of cancer therapy. Associations between post and pre-treatment levels (categorized as
above or below the sample baseline median) were examined. For LH, E2, and MOV,
relative impairment at baseline resulted in greater impairment after the end of cancer
therapy. Participants with baseline LH levels ≥4.5mIU/mL, E2 levels <40.4pg/mL, and
MOV measurements < 8.1cm3 had higher levels of LH (p=0.007), and lower levels of E2
(p=0.005) and MOV (p=0.027) after treatment compared to participants with hormone levels
outside of this range. While data showed a trend for other measures of ovarian reserves, they
did not reach statistical significance.
Exposure to alkylating agents was significantly associated with post-therapy impairment of
AMH, E2, INH, and AFC. Participants exposed to alkylating agents had AMH levels 76%
lower (p<0.001); E2 levels 13% lower (p=0.016); INH levels 54% lower (p<0.001); and
AFC 59% lower (p=0.004) at the end of cancer therapy compared to unexposed participants.
While the following associations did not reach statistical significance, alkylator exposure
was associated with 34% higher FSH levels (p=0.09), 51% higher LH levels (p=0.24) and
29% lower MOV (p=0.06) compared to unexposed. Length of treatment, age, menstrual
function, and pelvic/abdominal radiotherapy were not significantly associated with post-
therapy measures.
Finally, as expected, use of exogenous hormones during cancer therapy or at the first post-
treatment visit was associated with post-therapy levels of FSH and E2 (though not LH).
Participants who used hormones had post-treatment FSH levels 40% lower than those who
did not (p=0.001) and post-treatment E2 levels 77% higher than those who did not
(p=0.018).
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Longitudinal changes in measures of ovarian reserve post- therapy are shown in Table 3.
The average length of follow-up after the end of cancer therapy was 9.3 months (SD=2.9),
and the number of visits for each participant in the recovery phase ranged from 2–6. At the
end of follow-up, 9% (4/46) of participants had AMH levels that had returned to baseline
levels and 26% (12/46) had FSH values that had returned to pre-treatment values. Twenty
percent (9/46) showed no recovery in AMH levels.
In the models of recovery, FSH recovered at a rate of −7.0 % per month (p=0.01); LH at
−7.7% per month (p=0.007); E2 at 6.2% per month (p=.065); INH at 1.2% per month (p=.
64); MOV at 3.2% per month (p=.12) and AFC at 3.6% per month (p=.18). Models adjusted
for alkylator use, baseline measures of ovarian reserve, and exogenous hormone use for FSH
and E2, confirmed statistically significant changes for FSH, AMH, and MOV.
The rate of recovery for AMH was significantly impacted by pre-treatment AMH levels. For
participants who began with pre-treatment AMH levels < 2.0ng/mL, rate of recovery was
2.6% per month, whereas for those starting with pre-treatment AMH levels ≥2.0ng/mL,
recovery rate was 11.9% per month (interaction p-value=0.003). For other measures of
ovarian reserve, recovery rate was not significantly modified by other factors. Figure 1
demonstrates differences in rate of recovery for AMH depending on pre-treatment levels
(p=0.003) and differences in rate of recovery for AMH based on alkylator use (p=0.062).
Age, use of pelvic/abdominal radiotherapy, treatment length, exogenous hormone use, and
menstrual function were not significantly associated with recovery for any measure of
ovarian reserve. A subgroup analysis in participants not using hormonal contraceptives had
results of similar magnitude, as the coefficients in the restricted model differed from the
original by <3%.
Discussion
While cancer therapies have been shown to impair reproductive function in cancer survivors,
the acute impact of therapies on ovarian function in post-pubertal adolescents and young
women is not well documented. Future fertility is an important consideration for young
women newly diagnosed with cancer, and better methods are needed to predict long-term
reproductive potential in individual patients for counseling regarding fertility preservation
strategies (12, 13).
In this study, a comprehensive longitudinal assessment of ovarian reserve was completed in
young females with a new cancer diagnosis. Overall, we observed that ovarian reserve
became impaired acutely during treatment and then began to recover post-treatment. The
acute impairment of measures of ovarian reserve appears to occur as a result of
chemotherapy-related destruction of ovarian follicles. The recovery in these measures
reflects reinitiation of follicle growth after therapy. However, it must be emphasized that
primordial follicles destroyed during cancer therapy are irreversibly lost, thereby leading to
compromised ovarian reserve in survivors remote from therapy (5, 14).
In the current report, all measures of ovarian reserve demonstrated considerable acute
impairment after chemotherapy. The magnitude of acute impairment was associated with a
number of factors including baseline pre-treatment levels of ovarian reserve, use of
alkylators, and treatment duration. Participants exposed to alkylating agents had higher post-
treatment FSH and LH levels and lower AMH, E2, INH, and AFCs than those who did not
receive alkylators. Cancer treatment lasting > 90 days was also independently associated
with FSH impairment, and while a trend was seen for other hormone measures, no
statistically significant difference was noted, most likely due to sample size. This is a novel
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finding and potentially has important implications for oncologists designing therapies to
minimize ovarian toxicity.
Our study provides new information about the recovery of ovarian reserve post-treatment.
Over approximately 9 months post-therapy, models demonstrate that recovery rates depend
on baseline levels of ovarian reserve. Specifically, participants with baseline AMH levels
<2ng/mL demonstrate a recovery in AMH of 2.6% per month whereas participants with
baseline AMH levels ≥2ng/mL demonstrated a recovery rate of 11.9% per month.
Our findings are consistent with other studies assessing changes in reproductive function.
Similar to our findings, most measures of ovarian reserve fell rapidly during chemotherapy
in a study of 50 premenopausal breast cancer patients (median age 41 years) (8) and another
study of 26 breast cancer patients (median age 37 years) (15). In the latter study, AMH
levels remained suppressed over time while E2 and FSH levels returned to baseline by 6
months post-therapy. Similarly, we found that over nine months of post-therapy follow-up
AMH completely recovered in only 9% of participants. However, only 26% of participants
in the current study had complete recovery of FSH. Differences in age and length of follow-
up may account for some of the discrepancies observed between studies.
Our findings may also be compared to a study assessing changes in AMH in 30 women
treated for lymphoma using GnRH agonists. That study reported no recovery of AMH 12
months after therapy in participants receiving alkylator therapy (16). Unlike those findings,
in our study, exposure to alkylating agents appeared to be associated with a slower rate of
AMH recovery (though this did not meet statistical significance), but did not exclude the
possibility of recovery.
Many prospective studies in breast cancer patients have focused on predicting
chemotherapy-related amenorrhea as an outcome. For example, some studies have shown
that pre-treatment measures of AMH predict menstrual function 4–5 years after the end of
cancer therapy (9), while others do not (14). We found that menstrual function as an
outcome measure was particularly limited in our study population since participants were
younger than other cohorts and many used exogenous hormones. Indeed, we did not find an
association between measures of ovarian reserve and menstrual function. We believe that
measures of ovarian reserve provide a better assessment of reproductive function in this
population.
Data in survivors remote from treatment suggests that measures of ovarian reserve are
impaired when compared to similarly aged controls (5). Alkylating agents and pelvic
radiotherapy exposure correlate with degree of impairment. Our results confirm the
relationship of alkylating agents and decreased ovarian reserve. However, we failed to see
an association with pelvic radiotherapy, likely due to the limited number of exposed
participants, and because 1 of the 2 exposed to radiotherapy underwent ovarian
transposition.
One challenge of studying the reproductive risks of cancer therapy is that outcomes such as
fertility are difficult to capture. While other studies have demonstrated that AMH, and AFC
are the most sensitive measures of ovarian reserve in survivors (5), we did not detect
statistically significant associations with AFC likely because of the limited number of
women undergoing vaginal ultrasound.
While measures of ovarian reserve are a proxy for fertility and do not consistently predict
the ability to get pregnant, there is evidence in both natural conception and in vitro
fertilization populations that abnormal AMH and FSH values are associated with lower
fecundability and poorer response to fertility treatment (17, 18). All patients should be
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offered fertility preservation counseling prior to the onset of cancer therapy (13, 19). This
study provides valuable information for fertility preservation counseling, as we have shown
that women planning to receive alkylating agents, and especially those with low baseline
AMH, can expect slower recovery in ovarian reserve.
This study has several strengths. Recall bias was minimized by prospective enrollment and
confounding was reduced by restricting the study to non-pregnant, non-lactating females.
Cancer diagnoses and treatments were validated with medical records to diminish
misclassification bias. Unlike other prospective studies of hormone measurements, this
study included women with all types of cancer and only those who were 35 years or
younger. The statistical models used account for correlations within individuals and
variability in the timing of study visits. This study has one of the longest follow-up times of
any prospective study following measures of ovarian reserve.
Several limitations should be mentioned. A variety of diagnoses and treatments were
included in this study and therefore it was not possible to compare the effect of specific
chemotherapeutic regimens or fertility preservation techniques on ovarian reserve due to
limited sample size. Because of timing of other cancer-related appointments some visits
were not conducted during the early follicular phase, though unlike FSH, LH, and E2, AMH
and AFC may be less prone to variation during menstrual cycle (6, 20, 21). While there is
some evidence that AMH may be slightly lower in hormonal contraceptive users (22), other
reports have not confirmed this finding (7, 23). The inclusion of women on hormonal
contraceptives is an inherent limitation of any study assessing ovarian reserve in young
women with cancer at risk for pregnancy, as a significant proportion of this population uses
hormonal contraceptives for birth control and/or menstrual suppression. However, our
analysis suggests that hormone use was not a significant factor in our analyses for AMH.
Continued follow-up and new recruitment to this cohort will enable future analysis that will
overcome many of these limitations. Ultimately, more longitudinal data are needed to
identify factors associated with reproductive dysfunction after cancer therapy so that
clinically useful prediction tools can be developed. Such tools would improve patient
counseling regarding the risks and benefits of cancer therapies and technologies available
for fertility preservation.
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Refer to Web version on PubMed Central for supplementary material.
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Rate of Recovery of AMH After Cancer Therapy
2a: Blue: Pre-Treatment AMH >2. Slope is 11.7% per month.
Red: Pre-Treatment AMH≤2. Slope is 1.7% per month.
(Interaction P= 0.003)
Dashed lines=95% CI
2b: Blue: No alkylator use. Slope is 13.4% per month.
Red: Alkylator use. Slope is 4.9% per month.
(Interaction P= 0.062)
Dashed lines=95% CI
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Age (y), mean (range) 26.1 (15.0 – 35.9)
BMI, mean (range) 24.0 (16.9 – 39.6)
Race-Caucasian, % (n) 74 (34/46)
Education>College Graduate, % (n) 59 (27/46)
Income>75k, % (n) 37 (17/46)
Marital status-single, % (n) 70 (32/46)
Previous pregnancy, % (n) 24 (11/46)
Cancer Type and Regimen
 Breast, % (n) 41 (19/46)
  TCH 26 (5/19)
  TC 21 (4/19)
  ACT 47 (9/19)
  ECT 5 (1/19)
 Leukemia, % (n) 9 (4/46)
 Lymphoma, % (n) 28 (13/46)
  BEACOPP 31 (4/13)
  ABVD 46 (6/13)
  ABVE 8 (1/13)
  R-CHOP 8 (1/13)
  ICE 8 (1/13)
 Sarcoma, % (n) 9 (4/46)
 Brain, % (n) 2 (1/46)
 Wilm’s, % (n) 2 (1/46)
 Germ Cell, % (n) 2 (1/46)
 Other, % (n) 4 (2/46)
Alkylating agent use, % (n) 72 (33/46)
Alkylator score, mean (range) 1.4 (0 – 4)
Using exogenous hormones, % (n) 54 (25/46)
 Combined oral contraceptives 80 (20/25)
 Vaginal ring (Nuvaring) 12 (3/25)
 Progestin IUD 4 (1/25)
 Lupron Depot 4 (1/25)
Seen in early follicular phase, % (n) 54 (25/46)
Self-reported cycle length (d), mean (range)* 28 (21–32)
*
For participants not taking exogenous hormones
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